Cargando…
Heterologous Systemic Prime–Intranasal Boosting Using a Spore SARS-CoV-2 Vaccine Confers Mucosal Immunity and Cross-Reactive Antibodies in Mice as well as Protection in Hamsters
Background: Current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are administered systemically and typically result in poor immunogenicity at the mucosa. As a result, vaccination is unable to reduce viral shedding and transmission, ultimately failing to prevent infection. On...
Autores principales: | Katsande, Paidamoyo M., Fernández-Bastit, Leira, Ferreira, William T., Vergara-Alert, Júlia, Hess, Mateusz, Lloyd-Jones, Katie, Hong, Huynh A., Segales, Joaquim, Cutting, Simon M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692796/ https://www.ncbi.nlm.nih.gov/pubmed/36366408 http://dx.doi.org/10.3390/vaccines10111900 |
Ejemplares similares
-
Intranasal Treatment of Ferrets with Inert Bacterial Spores Reduces Disease Caused by a Challenging H7N9 Avian Influenza Virus
por: James, Joe, et al.
Publicado: (2022) -
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization
por: Lapuente, Dennis, et al.
Publicado: (2021) -
Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022) -
Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022) -
Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against Trypanosoma cruzi
por: Sanchez Alberti, Andrés, et al.
Publicado: (2020)